Theravance Biopharma’s Merger‑Triggered Insider Sale: Deepika Paki‑Nanathan Liquidates 58,065 Shares, Not a Sign of Distress, but a Standard Post‑Merger Settlement.
Theravance Biopharma insiders liquidated shares post‑merger with Zymeworks, showing a normal post‑merger payout, not a bearish signal. Read why it matters for investors.
7 minutes to read
